FAQ
Q: Should I prioritize testing for "total antibodies" or "antigen-specific antibodies"?
+
A: If your goal is to assess whether immunity has been established against
the target antigen, prioritize Antigen-specific IgG/IgM Total antibodies are more suitable as a
background reference, as they are easily influenced by individual immune status.
Q: Why is it recommended to test both IgM and IgG simultaneously?
+
A: IgM is more inclined towards early initiation, while IgG is more focused
on mature output. The combined detection of both is more effective in determining "whether initiation
has occurred and whether it has progressed to the mature stage," and is also more suitable for comparing
differences in immunization protocols.
Q: Does an increase in IgG indicate "protective immunity"?
+
A: Not necessarily. The protective efficacy of many vaccines is related to
antibodies, but it still depends on the function and quality of the antibodies (such as neutralizing
ability, affinity maturation, etc.). Therefore, it is recommended to at least include "quality
indicators" (such as avidity) or functional assays.
Q: Why is IL-21 so critical in humoral immunity?
+
A: IL-21 is a key effector molecule of Tfh cells, closely associated with
germinal center reactions and the formation of high-affinity antibodies. As an enhanced indicator, it is
more suitable for explaining "why this group exhibits more complete maturation."
Q: What do IgG subtypes (IgG1/IgG2a, etc.) indicate?
+
A: It is more suitable for stratifying "immune bias clues" (for example,
different adjuvants/infection types shape different biases). It is recommended to read in conjunction
with the project background/cytokine clues (such as IL-4/IFN-γ) to avoid drawing conclusions based on a
single indicator.
Q: I see that IgM remains consistently high while IgG does not increase. What are the common
reasons for this?
+
A: Possible reasons include an insufficient time window, inadequate T-cell
help, suboptimal antigen/adjuvant design, or a model inherently biased toward T-independent responses.
It is recommended to extend the time points and consider incorporating helper signals such as IL-21 for
mechanistic insights.
Q: How to assess "whether antibodies are long-lasting"?
+
A: The most direct method is to do it. Long-term follow-up curve of
specific IgG. If the titer remains stable or declines slowly, it suggests good durability; a
rapid decline indicates insufficient durability.
Q: Does an elevated BAFF/APRIL level indicate "more long-lived plasma cells"?
+
A: It is not advisable to draw such direct inferences. BAFF/APRIL is better
suited as an indicative reading for "maintaining a supportive environment" and must be interpreted
alongside long-term titer trends.
Q: If the antibody titer is not increasing, what should I check first?
+
A: Priority Investigation: Immunization protocol (dose/interval), sampling
time points, antigen preparation and storage, and the presence of inhibitory background (refer to Topic
4 if needed). Use helper signals such as IL-21 for mechanistic insights when necessary.
